研究背景：幽門桿菌和消化性潰瘍兩者之關聯已被許多研究證實，在經過根除療法
治療後，潰瘍之復發率明顯下降。
研究方法：本研究是以健保資料庫台灣地區2005年，具消化性潰瘍診斷碼病患隨機
抽取二分之一作為研究對象，進行根除療法在台灣地區之流行病學分析。
結果：在所獲得資料中，本研究接受根除療法之病患共計88,900人次，男性為
48,920人次，占55.03%；女性為39,980人次，佔44.97%。在年齡層方面，42歲至64歲年
齡層接受根除療法及總藥費所佔比率最高；病患年齡層越大，所接受處方之天數越長藥
費越多；醫療層級越高，所開立處方之天數越長藥費也越多。根除療法藥物組合，二合
一療法佔了超過70%，與1997年亞洲泛太平洋幽門桿菌處置共識研討會報告所建議之根
除療法不符計約87.7%。
結論：台灣醫師在開立根除療法藥物組合上大部分是不符合亞洲泛太平洋幽門桿菌
處置共識研討會報告所建議之處方組合；為了提升醫療品質，或許需要藉著適當的繼續
教育，推廣幽門桿菌相關知識讓第一線醫師充分了解而來改善。

The relationship about helicobacter pylori and peptic ulcer disease has been confirmed by many clinical studies. After eradication therapy, the recurrence of peptic ulcer disease declined significantly.
We collected the claim data of National Health Insurance database of Taiwan in 2005. Half of the persons with peptic ulcer disease, by ICD-9 codes, were selected for further epidemiology analysis of Helicobacter Pylori eradication therapy.
There are 88,900 prescriptions, with male 48,920 ( 55.03 %) and female 39,980( 44.97%) ,receiving eradication therapy. Descriptive analysis demonstrated the age group of 40-64 accounts for the peak of receiving eradication therapy, and has the highest total cost of prescribed medicine. The older the age group, the longer the prescribed days and the higher the prescribed cost. The higher the level of medical organization is, the longer the prescribed days and the higher the average cost of prescribed medicine are. In eradication therapy, the regimens of dual therapy accounted for more than 70 percentages of all prescriptions. Most of the regimens, 87.7% of all prescriptions, are not complied with the suggested therapy by the Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection.
Because most of the eradication therapy prescribed in Taiwan didn’t complied with the suggested regimen in 2005,continue medical education about the eradication therapy of Helicobacter pylori should be considered, especially for the primary care physicians.